<DOC>
	<DOCNO>NCT02080780</DOCNO>
	<brief_summary>The purpose study evaluate drug-drug interaction potential clarithromycin XL Diltiazem hydrochloride ( DTZ ) 2 % cream .</brief_summary>
	<brief_title>Study Evaluate Interaction Potential Clarithromycin XL Diltiazem Hydrochloride Cream 2 % Healthy Subjects</brief_title>
	<detailed_description>This study design investigate potential effect clarithromycin XL steady state ( administer orally , daily Days 4 9 2 x 500 mg tablet , 1000 mg per day , total 6000 mg ) PK single topical dose diltiazem hydrochloride 2 % cream apply perianal area ( ~2.5 cm [ 1 inch ] ; ~8.5 mg ) . This Phase 1 study single treatment arm . Efficacy assess ; therefore study open-label design .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>1 . Were healthy subject ( confirm medical history , laboratory work , physical exam ) ; 2 . Were 18 60 year age , inclusive ; 3 . If childbearing potential , use acceptable form birth control ( ie , nonhormonal intrauterine device , diaphragm , condom , bilateral tubal ligation , abstinence , monogamous relationship partner vasectomy ) ; 4 . In case female childbearing potential , negative serum pregnancy test ( SPT ) Screening negative urine pregnancy test ( UPT ) Study Day 1 , ( woman consider childbearing potential unless postmenopausal least 12 month surgically sterile [ hysterectomy , bilateral oophorectomy ] ) ; 5 . Had clinical lab test ( hematology , chemistry , urinalysis ) , electrocardiogram ( ECG ) , vital sign within normal limit , assess investigator clinical significance ; 6 . Were able read , understand , provide sign informed consent . 1 . On drug treatment time study ; 2 . Had donate plasma ( 500 mL ) within 7 day prior drug administration ; 3 . Had donate lose whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 499 mL whole blood within 30 day , 499 mL whole blood within 56 day prior drug administration ; 4 . Were use unwilling stop concomitant topical preparation around anus perianal area Day −1 end study ; 5 . Had hypersensitivity allergy investigational compound/compound class use study , bacterial fighting medication , include limited clarithromycin XL , azithromycin , telithromycin , erythromycin calcium channel blocker ; 6 . Had history presence neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease , , opinion investigator , could interfere study conduct observation ; 7 . Were unable adhere understand requirement protocol ; 8 . Had body mass index &gt; 40 kg/m2 ; 9 . Had screen ECG &gt; 470 QTCF female &gt; 450 QTCF male ; 10 . Were active treatment antiviral therapy ( eg , indinavir , nelfinavir , ritonavir ) human immunodeficiency virus ( HIV ) ; 11 . Had treat follow medication within 14 day prior sign ICF : CYP450 inhibitor inducer ; CYP3A4 substrates , inhibitor , inducer ; Benzodiazepines ; βadrenoceptor antagonist ( betablockers ) ; Calcium channel blocker ; Digoxin ; Investigational agent ; Opioids . 12 . Had follow concomitant disease state : Sick sinus syndrome except presence function ventricular pacemaker ; Secondor thirddegree atrioventricular block except presence function ventricular pacemaker ; Hypotension ( &lt; 90 mm Hg systolic ) ; Acute myocardial infarction pulmonary congestion document xray ; History clinically significant renal disease ; History clinically significant Alzheimer 's Parkinson 's disease ; History clinically significant hepatic disease ; Current infection treat macrolide antibiotic ; Clinical evidence history fecal incontinence ; Clinical evidence history anal fistula ; Clinical evidence history anal abscess ; History inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) ; History prior anal rectal surgery include limited : lateral sphincterotomy anal stretch ; 13 . Had major organ transplant ; 14 . Had serious illness 4 week precede begin treatment ( ie , result missed work hospitalization ) ; 15 . Had receive treatment type internal cancer within 5 year prior enrollment ; 16 . Had , opinion investigator , clinically significant abnormal clinical laboratory result time screen ; 17 . Were female pregnant , plan become pregnant study , breastfeed child ; 18 . Were currently use narcotic chronically ; 19 . Were currently smoker ; 20 . Had use investigational drug participate investigational study within 30 day prior dose ; 21 . Had use prescription medication within 14 day prior administration study medication overthecounter ( OTC ) product ( include natural food supplement vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption ; 22 . Were employee , family member , student investigator clinical site ; 23 . Had food allergy , intolerance , restriction , special diet , opinion investigator , could contraindicate subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>